Phosphinic peptides as zinc metalloproteinase inhibitors

Cellular and Molecular Life Sciences

Volumn 61, Issue 16, 2004, Pages 2010-2019

  Dive, V ^a   Georgiadis, D ^b   Matziari, M ^b   Makaritis, A ^b   Beau, F ^a   Cuniasse, P ^a   Yiotakis, A ^b  

^a CEA SACLAY   (France)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

ACE; Inhibitors; MMPs; Phosphinic; Transition state; Zinc proteases

Indexed keywords

FOSINOPRILAT; METALLOPROTEINASE INHIBITOR; PEPTIDE DERIVATIVE; PHOSPHINIC ACID DERIVATIVE; RXP 03; RXP 407; RXP A 380; ZINC DERIVATIVE;

CHEMISTRY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; IN VIVO STUDY; MOLECULAR DYNAMICS; REVIEW;

EID: 4344573848     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4050-y     Document Type: Review

References (43)

1. Grobelny D., Goli U. B. and Galardy R. E. (1989) Binding energetics of phosphorus-containing inhibitors of thermolysin. Biochemistry 28: 4948-4951
2. Yiotakis A., Lecoq A., Nicolaou A., Labadie J. and Dive V. (1994) Phosphinic peptide analogues as potent inhibitors of Corynebacterium rathayii bacterial collagenase. Biochem. J. 303 (Pt 1): 323-327
3. Yiotakis A., Lecoq A., Vassiliou S., Raynal I., Cuniasse P. and Dive V. (1994) Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase. J. Med. Chem. 37: 2713-2720
4. Dive V., Lucet-Levannier K., Georgiadis D., Cotton J., Vassiliou S., Cuniasse P. et al. (2000) Phosphinic peptide inhibitors as tools in the study of the function of zinc metallopeptidases. Biochem. Soc. Trans. 28: 455-460
5. Collinsova M. and Jiracek J. (2000) Phosphinic acid compounds in biochemistry, biology and medicine. Curr. Med. Chem. 7: 629-647
6. Dreyer G. B., Metcalf B. W., Tomaszek T. A. Jr, Carr T. J., Chandler A. C. 3rd, Hyland L. et al. (1989) Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc. Natl. Acad. Sci. USA 86: 9752-9756
7. Puente X. S., Sanchez L. M., Overall C. M. and Lopez-Otin C. (2003) Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4: 544-558
8. Lopez-Otin C. and Overall C. M. (2002) Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol. 3: 509-519
9. Valiaeva N., Bartley D., Konno T. and Coward J. K. (2001) Phosphinic acid pseudopeptides analogous to glutamyl-gamma-glutamate: synthesis and coupling to pteroyl azides leads to potent inhibitors of folylpory-gamma-glutamate synthetase. J. Org. Chem. 66: 5146-5154
10. McGuire J. J., Haile W. H., Valiaeva N., Bartley D., Guo J. and Coward J. K. (2003) Potent inhibition of human folylpolyglutamate synthetase by a phosphinic acid mimic of the tetrahedral reaction intermediate. Biochem. Pharmacol. 65: 315-318
11. Jiracek J., Yiotakis A., Vincent B., Lecoq A., Nicolaou A., Checler F. et al. (1995) Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24-15 using combinatorial chemistry. J. Biol. Chem. 270: 21701-21706
12. Grams F., Dive V., Yiotakis A., Yiallouros I., Vassiliou S., Zwilling R. et al. (1996) Structure of astacin with a transition-state analogue inhibitor. Nat. Struct. Biol. 3: 671-675
13. Gall A. L., Ruff M., Kannan R., Cuniasse P., Yiotakis A., Dive V. et al. (2001) Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J. Mol. Biol. 307: 577-586.
14. Yiallouros I., Grosse Berkhoff E. and Stocker W. (2000) The roles of Glu93 and Tyr149 in astacin-like zinc peptidases. FEBS Lett 484: 224-228
15. Yiotakis A., Vassiliou S., Jiracek J. and Dive V. (1996) Protection of the hydroxyphosphinyl function of phosphinic dipeptides by adamantyl. Application to the solid-phase synthesis of phosphinic peptides. J. Org. Chem. 61: 6601-6605
16. Buchardt J. and Meldal M. (2000) Novel methodology for the solid-phase synthesis of phosphinic peptides. J. Chem. Soc. Perkin Trans. 1: 3306-3310
17. Gurulingappa H., Buckhaults P., Kumar S. K., Kinzler K. W., Vogelstein B. and Khan S. R. (2003) Dosing, synthesis and evaluation of new RDP inhibitors. Tetrahedron Lett. 44: 1871-1873
18. Schiodt C. B., Buchardt J., Terp G. E., Christensen U., Brink M., Berger Larsen Y. et al. (2001) Phosphinic peptide inhibitors of macrophage metalloelastase (MMP-12). Selectivity and mechanism of binding. Curr Med Chem 8: 967-976
19. Chen H., Noble F., Mothe A., Meudal H., Coric P., Danascimento S. et al. (2000) Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities. J. Med. Chem. 43: 1398-1408
20. Jiracek J., Yiotakis A., Vincent B., Checler F. and Dive V. (1996) Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. J. Biol. Chem. 271: 19606-19611
21. Dive V., Cotton J., Yiotakis A., Michaud A., Vassiliou S., Jiracek J. et al. (1999) RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. USA 96: 4330-4335
22. Matziari M., Georgiadis D., Dive V. and Yiotakis A. (2001) Convenient synthesis and diversification of dehydroalaninyl phosphinic peptide analogues. Org. Lett. 3: 659-662
23. Makaritis A., Georgiadis D., Dive V. and Yiotakis A. (2003) Diastereoselective solution and multipin-based combinatorial array synthesis of a novel class of potent phosphinic metalloprotease inhibitors. Chemistry 9: 2079-2094
24. Overall C. M. and Lopez-Otin C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2: 657-672
25. Babine R. E. and Bender S. L. (1997) Molecular recognition of protein - Ligand complexes: applications to drug design. Chem. Rev. 97: 1359-1472
26. Whittaker M., Floyd C. D., Brown P. and Gearing A. J. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99: 2735-2776
27. Amour A., Slocombe P. M., Webster A., Butler M., Knight C. G., Smith B. J. et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435: 39-44
28. Amour A., Hutton M., Knauper V., Slocombe P. M., Webster A., Butler M. et al. (1999) Inhibition of the metalloproteinase domain of mouse TACE. Ann. N. Y. Acad. Sci. 878: 728-731
29. Turk B. E., Wong T. Y., Schwarzenbacher R., Jarrell E. T., Leppla S. H., Collier R. J. et al. (2004) The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11: 60-66
30. Porter J. R., Beelay N. R. A., Boyce B. A., Mason B., Millican A., Millar K. et al. (1994) Potent and selective inhibitor of gelatinase A 1. Hydroxamic acid derivatives. Bioorg. Med. Chem. Lett. 4: 2741-2746
31. Caldwell C. G., Sahoo S. P., Polo S. A., Eversole R. R., Lanza T. J., Mills S. G. et al. (1996) Phosphinic acid inhibitors of matrix metalloproteases. Bioorg. Med. Chem. Lett. 6: 323-328
32. Vassiliou S., Mucha A., Cuniasse P., Georgiadis D., Lucet-Levannier K., Beau F. et al. (1999) Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J. Med. Chem. 42: 2610-2620
33. Acharya K. R., Sturrock E. D., Riordan J. F. and Ehlers M. R. (2003) Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug. Discov. 2: 891-902
34. Natesh R., Schwager S. L., Sturrock E. D. and Acharya K. R. (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421: 551-554
35. Georgiadis D., Beau F., Czarny B., Cotton J., Yiotakis A. and Dive V. (2003) Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ. Res. 93: 148-154
36. Georgiadis D., Dive V. and Yiotakis A. (2001) Synthesis and comparative study on the reactivity of peptidyl-type phosphinic esters: intramolecular effects in the alkaline and acidic cleavage of methyl beta-carboxyphosphinates. J. Org. Chem. 66: 6604-6610
37. Cursio R., Mari B., Louis K., Rostagno P., Saint-Paul M. C., Giudicelli J. et al. (2002) Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 16: 93-95
38. Freestone T., Turner R. J., Coady A., Higman D. J., Greenhalgh R. M. and Powell J. T. (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 15: 1145-1151
39. Grembecka J., Mucha A., Cierpicki T. and Kafarski P. (2003) The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J. Med. Chem. 46: 2641-2655
40. Jozic D., Bourenkow G., Bartunik H., Scholze H., Dive V., Henrich B. et al. (2002) Crystal structure of the dinuclear zinc aminopeptidase PepV from Lactobacillus delbrueckii unravels its preference for dipeptides. Structure (Camb) 10: 1097-1106
41. Jozic D., Kaiser J. T., Huber R., Bode W. and Maskos K. (2003) X-ray structure of isoaspartyl dipeptidase from E. coli: a dinuclear zinc peptidase evolved from amidohydrolases. J. Mol. Biol. 332: 243-256
42. Collinsova M., Castro C., Garrow T. A., Yiotakis A., Dive V. and Jiracek J. (2003) Combining combinatorial chemistry and affinity chromatography: highly selective inhibitors of human betaine: homocysteine S-methyltransferase. Chem. Biol. 10: 113-122
43. Chen H., Noble F., Roques B. P. and Fournie-Zaluski M. C. (2001) Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs. J. Med. Chem. 44: 3523-3530